Heidelberg Pharma AG (ETR:HPHA) | Finanzwire

Basculer en Français

9715	Companies
193814	Keywords
125022	Articles
103149	Press releases

Home
Companies
Heidelberg Pharma AG

BRIEF

published on 10/23/2025 at 08:02, 2 months 29 days ago

Heidelberg Pharma's HDP-101 Receives Fast Track Designation from FDA

FDA Heidelberg Pharma HDP-101 Multiple Myeloma Fast Track Designation
PRESS RELEASE

published on 10/23/2025 at 07:57, 2 months 29 days ago

Heidelberg Pharma’s Lead ADC Candidate HDP-101 Granted Fast Track Designation by US FDA for the Treatment of Multiple Myeloma
Heidelberg Pharma's lead ADC candidate HDP-101 granted Fast Track Designation by US FDA for the treatment of multiple myeloma. Accelerated review for innovative cancer therapy

Heidelberg Pharma Multiple Myeloma Fast Track Designation ADC Candidate US FDA
BRIEF

published on 10/09/2025 at 07:08, 3 months 12 days ago

Heidelberg Pharma's Nine-Month Update for 2025

Financial Results Clinical Trials Heidelberg Pharma HDP-101 Strategy Adjustment
PRESS RELEASE

published on 10/09/2025 at 07:03, 3 months 12 days ago

Heidelberg Pharma Reports on the First Nine Months of Financial Year 2025
Heidelberg Pharma AG reports operational progress and financial figures for the first nine months of fiscal year 2025, focusing on lead ADC candidate HDP-101 and cost-saving measures

Financial Report Clinical Trial Cost-saving Measures Heidelberg Pharma AG ADC Candidate
BRIEF

published on 10/06/2025 at 16:03, 3 months 15 days ago

Heidelberg Pharma AG Revises Financial Guidance for 2025

Financial Guidance Heidelberg Pharma ADCs Operating Expenses Cash Requirements
PRESS RELEASE

published on 10/06/2025 at 15:58, 3 months 15 days ago

EQS-Adhoc: Heidelberg Pharma AG Announces Updated Guidance
Heidelberg Pharma AG adjusts its financial guidance for 2025, focusing on cost-saving measures. Sales, operating expenses, and cash requirements revised

Sales Financial Guidance Cost-saving Measures Heidelberg Pharma AG Operating Expenses
BRIEF

published on 09/25/2025 at 13:22, 3 months 26 days ago

Heidelberg Pharma Advances HDP-101 in Clinical Trial for Multiple Myeloma

HDP-101 Multiple Myeloma Safety Profile Phase I/IIa Trial Clinical Activity
PRESS RELEASE

published on 09/25/2025 at 13:17, 3 months 26 days ago

Heidelberg Pharma Advances to Cohort 9 in Phase I/IIa Trial of Lead ATAC Candidate HDP-101 in Multiple Myeloma
Heidelberg Pharma advances to Cohort 9 in Phase I/IIa trial of lead ATAC candidate HDP-101 in multiple myeloma, demonstrating favorable safety profile and early signs of clinical activity

Heidelberg Pharma Multiple Myeloma ATAC Candidate Phase I/IIa Trial Clinical Activity
BRIEF

published on 09/25/2025 at 10:56, 3 months 26 days ago

Heidelberg Pharma Adjusts Strategy Amid Financial Delays

Cost Reduction Strategic Focus Heidelberg Pharma Milestone Payment ADC Candidate
BRIEF

published on 09/25/2025 at 10:51, 3 months 26 days ago

Heidelberg Pharma Reduces Costs and Focuses on HDP-101 Amid Payment Delay

Cost Reduction Heidelberg Pharma HDP-101 ADC Development Milestone Payment Delay

Accesswire

Published on 01/22/2026 at 00:00, 4 hours 57 minutes ago

Onco-Innovations Engages i2i Marketing Group Engagement for Market Awareness Services
Published on 01/22/2026 at 00:00, 4 hours 57 minutes ago

TDG Gold Corp. Grants Stock Options
Published on 01/22/2026 at 00:00, 4 hours 57 minutes ago

FutureGen Industries Provides Shareholder Update on Expanded Investment Strategy in High-Growth Technology Sectors
Published on 01/21/2026 at 23:30, 5 hours 27 minutes ago

Galway Metals Reports Robust PEA Results with 33% and 61% After Tax IRR, Using both Long Term and Spot Pricing Scenarios, Respectively
Published on 01/21/2026 at 22:45, 6 hours 12 minutes ago

Premier American Uranium Announces Bought Deal Private Placement for Gross Proceeds of C$10 Million

View all ACCESSWIRE

EQS Group

Published on 01/22/2026 at 01:33, 3 hours 23 minutes ago

EQS-Adhoc: ADTRAN Holdings, Inc.: Preliminary revenue above guidance and non-GAAP earnings per share above analyst consensus for Q4 2025
Published on 01/21/2026 at 22:11, 6 hours 45 minutes ago

SNP Remains on Growth Trajectory in 2025 with Third Consecutive Record Year
Published on 01/21/2026 at 21:09, 7 hours 48 minutes ago

EQS-Adhoc: Deutsche Börse AG: Deutsche Börse AG and Allfunds Group plc reached an agreement on recommended acquisition by Deutsche Börse AG of Allfunds Group plc
Published on 01/21/2026 at 17:47, 11 hours 10 minutes ago

CPI PROPERTY GROUP – Sustainable Finance Update
Published on 01/21/2026 at 16:51, 12 hours 5 minutes ago

EQS-Adhoc: SNP SE: Revenue and EBIT in Fiscal Year 2025 Better Than Expected

Les Echos

Published on 01/21/2026 at 17:40, 11 hours 17 minutes ago

Eiffage wins in consortium the contract to replace the steel bridge over the Kiel Canal in Germany
Published on 01/21/2026 at 08:45, 20 hours 12 minutes ago

ENGIE signs a 10-year Biomethane Purchase Agreement with PepsiCo, its first in the United Kingdom
Published on 01/20/2026 at 17:59, 1 day 10 hours ago

Statement of transactions in own shares from January 14, 2026 to January 16, 2026
Published on 01/20/2026 at 17:45, 1 day 11 hours ago

Change in Baikowski® executive management
Published on 01/20/2026 at 07:30, 1 day 21 hours ago

Gimv leads € 51 million Series B investment round in Exciva to advance innovative Alzheimer’s therapy

View all LES ECHOS COMFI WIRE